SHARE

KollagenX Corp (OTCMKTS:KGNX) has been in a strong uptrend over the last couple of trading sessions ever since it formed a good support near the $0.135. The strong price volume action has meant that the stock has been able to move above the resistance zone at $0.19 which is also the 50 day moving average and is being seen as a huge positive. The relative strength index for the stock has given a buy signal indicative of the shift of momentum towards the buy side. Traders believe that the stock could head to levels of $0.229 in the near term.

kgnx

KollagenX Corp (OTCMKTS:KGNX) is summoning a partnership with Samson Pharmaceuticals as part of its strategy to expand its 24kt Gold Skin Care products.

The company’s management has approached Samson Pharmaceuticals because they believe the latter is the best firm suited for the task. Above the list of reasons for the selection was the fact that Samson Pharmaceuticals is registered by the FDA. They also have licensed labs for manufacturing drugs and also uphold a credible portfolio of products including dietary supplements, cosmetics, OTC products and others.

KollagenX believes that Samson Pharmaceuticals is well equipped to handle the demanding nature of expanding the product line. It also has the right understanding of the distribution methods necessary for the mission to be successful. KollagenX is focused on providing eco-friendly and affordable cosmetic products that play an important role in people’s lives. The firm offers unique products thanks to nano gold technology.

Some of the most successful products from the company include the special anti-aging products that help the skin to maintain its natural glow and remain healthier and beautiful. The firm has therefore managed to build up a successful reputation since it was formed in 2008. The future also looks bright as plans for expansion fall into place.

An analysis of the cosmetics market reveals that the industry expanded by about 5% in 2010 resulting in sales of more than 11 billion units and revenues above $78 million. The cosmetics industry expanded further from 2010 to up to now by roughly 21%. As a result, sales have risen beyond 13 billion units while revenues reach highs of $95 billion.

A large percent of the numbers represent facial care products while the company’s biggest market is Asia Pacific. The firm estimates that the industry will maintain its positive growth trend in the future, thus the need to position itself for better times ahead. An expanded product line will, therefore, be ideal for the future of KollagenX.